2017 | Phase Ib study of codrituzumab in combination with sorafenib in patients with non-curable advanced hepatocellular carcinoma (HCC) | Abou-Alfa, GK; Yen, CJ; Hsu, CH; O'Donoghue, J; Beylergil, V; Ruan, ST; Pandit-Taskar, N; Gansukh, B; Lyashchenko, SK; Ma, J; Wan, P; Shao, YY; Lin, ZZ; Frenette, C; O'Neil, B; Schwartz, L; Smith-Jones, PM; Ohtomo, T; Tanaka, T; Morikawa, H; Maki, Y; Ohishi, N; Chen, YC; Agajanov, T; Boisserie, F; Di Laurenzio, L; Lee, R; Larson, SM; Cheng, AL; Carrasquilo, JA | CANCER CHEMOTHERAPY AND PHARMACOLOGY | | | |